论文部分内容阅读
目的对配体介导的纳米脂质体作为肿瘤疫苗载体的可行性进行评价。方法建立体外树突状细胞(dendritic cells,DC)模型,考察DC对配体介导纳米脂质体的摄取行为;建立S180荷瘤鼠模型,考察配体介导纳米脂质体对荷瘤鼠的免疫效果。结果 DEC205单克隆抗体介导的纳米脂质体能被DC细胞特异性识别,提高摄取效率,同时也能显著抑制肿瘤生长,延长小鼠存活时间,在整个免疫周期内均能保持较高的IL-12和IFN-γ水平,对S180荷瘤鼠具有明显的免疫治疗作用。结论配体介导的纳米脂质体能够产生有效的抗肿瘤免疫应答,可以作为治疗型肿瘤疫苗的载体。
Objective To evaluate the feasibility of ligand-mediated nanoliposomes as tumor vaccine carriers. Methods Dendritic cells (DC) models were established in vitro to investigate the uptake of ligand-mediated nanoliposomes by DCs. S180 tumor-bearing mice model was established to investigate the effect of ligand-mediated nanoliposomes on tumor-bearing mice The immune effect. Results The DEC205 monoclonal antibody-mediated nanosomes could be recognized by DCs specifically to improve the uptake efficiency and inhibit the tumor growth and prolong the survival time of mice, and maintain high IL- 12 and IFN-γ levels, S180 tumor-bearing mice with significant immunotherapy. Conclusion Ligand-mediated nanoliposomes can produce an effective anti-tumor immune response and can be used as a carrier for therapeutic tumor vaccines.